Contact Lenses - Medical Devices Pipeline Assessment, 2017

Publisher Name :
Date: 01-Aug-2017
No. of pages: 204

Contact Lenses - Medical Devices Pipeline Assessment, 2017

Summary

GlobalData's Medical Devices sector report, "Contact Lenses - Medical Devices Pipeline Assessment, 2017" provides an overview of Contact Lenses currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Contact Lenses pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Contact Lenses under development

- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

- The report reviews the major players involved in the development of Contact Lenses and list all their pipeline projects

- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

- The report provides key clinical trial data of ongoing trials specific to pipeline products

- Recent developments in the segment / industry

Reasons to buy

The report enables you to -

- Formulate significant competitor information, analysis, and insights to improve R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of Contact Lenses under development

- Develop market-entry and market expansion strategies

- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

- In-depth analysis of the product's current stage of development, territory and estimated launch date

Contact Lenses - Medical Devices Pipeline Assessment, 2017

Table of Contents
1 Table of Contents 2
1.1 List of Tables 7
1.2 List of Figures 11
2 Introduction 12
2.1 Contact Lenses Overview 12
3 Products under Development 13
3.1 Contact Lenses - Pipeline Products by Stage of Development 13
3.2 Contact Lenses - Pipeline Products by Segment 14
3.3 Contact Lenses - Pipeline Products by Territory 15
3.4 Contact Lenses - Pipeline Products by Regulatory Path 16
3.5 Contact Lenses - Pipeline Products by Estimated Approval Date 17
3.6 Contact Lenses - Ongoing Clinical Trials 18
4 Contact Lenses - Pipeline Products under Development by Companies 19
4.1 Contact Lenses Companies - Pipeline Products by Stage of Development 19
4.2 Contact Lenses - Pipeline Products by Stage of Development 21
5 Contact Lenses Companies and Product Overview 23
5.1 Aeon Astron Corporation Company Overview 23
5.1.1 Aeon Astron Corporation Pipeline Products & Ongoing Clinical Trials Overview 23
5.2 Alcon Laboratories Inc Company Overview 25
5.2.1 Alcon Laboratories Inc Pipeline Products & Ongoing Clinical Trials Overview 25
5.3 Apeliotus Ophthalmics (Inactive) Company Overview 33
5.3.1 Apeliotus Ophthalmics (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 33
5.4 Auburn University Company Overview 35
5.4.1 Auburn University Pipeline Products & Ongoing Clinical Trials Overview 35
5.5 Axcelon Biopolymers Corp. Company Overview 36
5.5.1 Axcelon Biopolymers Corp. Pipeline Products & Ongoing Clinical Trials Overview 36
5.6 Bar-Ilan University Company Overview 37
5.6.1 Bar-Ilan University Pipeline Products & Ongoing Clinical Trials Overview 37
5.7 Bausch & Lomb Inc Company Overview 38
5.7.1 Bausch & Lomb Inc Pipeline Products & Ongoing Clinical Trials Overview 38
5.8 Children's Hospital Boston Company Overview 42
5.8.1 Children's Hospital Boston Pipeline Products & Ongoing Clinical Trials Overview 42
5.9 CooperVision Inc Company Overview 43
5.9.1 CooperVision Inc Pipeline Products & Ongoing Clinical Trials Overview 43
5.10 EP Global Communications, Inc. Company Overview 48
5.10.1 EP Global Communications, Inc. Pipeline Products & Ongoing Clinical Trials Overview 48
5.11 Euclid Systems Corp Company Overview 49
5.11.1 Euclid Systems Corp Pipeline Products & Ongoing Clinical Trials Overview 49
5.12 e-Vision Medical Devices, Inc. Company Overview 50
5.12.1 e-Vision Medical Devices, Inc. Pipeline Products & Ongoing Clinical Trials Overview 50
5.13 Eyenovations Company Overview 51
5.13.1 Eyenovations Pipeline Products & Ongoing Clinical Trials Overview 51
5.14 EyeYon Medical Company Overview 52
5.14.1 EyeYon Medical Pipeline Products & Ongoing Clinical Trials Overview 52
5.15 Imperial College London Company Overview 53
5.15.1 Imperial College London Pipeline Products & Ongoing Clinical Trials Overview 53
5.16 Johnson & Johnson Vision Care Inc Company Overview 54
5.16.1 Johnson & Johnson Vision Care Inc Pipeline Products & Ongoing Clinical Trials Overview 54
5.17 Massachusetts Eye and Ear Infirmary Company Overview 56
5.17.1 Massachusetts Eye and Ear Infirmary Pipeline Products & Ongoing Clinical Trials Overview 56
5.18 Novartis AG Company Overview 57
5.18.1 Novartis AG Pipeline Products & Ongoing Clinical Trials Overview 57
5.19 Ocular Dynamics, LLC Company Overview 58
5.19.1 Ocular Dynamics, LLC Pipeline Products & Ongoing Clinical Trials Overview 58
5.20 Ocutec Ltd Company Overview 59
5.20.1 Ocutec Ltd Pipeline Products & Ongoing Clinical Trials Overview 59
5.21 Presbia Plc Company Overview 60
5.21.1 Presbia Plc Pipeline Products & Ongoing Clinical Trials Overview 60
5.22 RetMap Inc Company Overview 63
5.22.1 RetMap Inc Pipeline Products & Ongoing Clinical Trials Overview 63
5.23 Stanford University Company Overview 64
5.23.1 Stanford University Pipeline Products & Ongoing Clinical Trials Overview 64
5.24 SynergEyes Inc Company Overview 65
5.24.1 SynergEyes Inc Pipeline Products & Ongoing Clinical Trials Overview 65
5.25 The Hong Kong University of Science and Technology Company Overview 67
5.25.1 The Hong Kong University of Science and Technology Pipeline Products & Ongoing Clinical Trials Overview 67
5.26 The University of New South Wales Company Overview 68
5.26.1 The University of New South Wales Pipeline Products & Ongoing Clinical Trials Overview 68
5.27 UltraVision CLPL Company Overview 69
5.27.1 UltraVision CLPL Pipeline Products & Ongoing Clinical Trials Overview 69
5.28 University of California San Diego Company Overview 70
5.28.1 University of California San Diego Pipeline Products & Ongoing Clinical Trials Overview 70
5.29 University of Florida Company Overview 72
5.29.1 University of Florida Pipeline Products & Ongoing Clinical Trials Overview 72
5.30 University of Valencia Company Overview 73
5.30.1 University of Valencia Pipeline Products & Ongoing Clinical Trials Overview 73
5.31 University of Washington Company Overview 75
5.31.1 University of Washington Pipeline Products & Ongoing Clinical Trials Overview 75
5.32 Valeant Pharmaceuticals International Inc Company Overview 77
5.32.1 Valeant Pharmaceuticals International Inc Pipeline Products & Ongoing Clinical Trials Overview 77
5.33 Visioneering Technologies Inc Company Overview 90
5.33.1 Visioneering Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 90
5.34 VISTAKON Pharmaceuticals LLC Company Overview 94
5.34.1 VISTAKON Pharmaceuticals LLC Pipeline Products & Ongoing Clinical Trials Overview 94
5.35 Yolia Health Company Overview 95
5.35.1 Yolia Health Pipeline Products & Ongoing Clinical Trials Overview 95
6 Contact Lenses- Recent Developments 96
6.1 Jul 13, 2017: Visioneering Technologies Appoints Michelle Kirst as Territory Manager for New Jersey 96
6.2 Jul 11, 2017: Visioneering Technologies Appoints Ron Makelke as Territory Manager for San Francisco 96
6.3 Jul 06, 2017: Bausch + Lomb Japan Launches Bausch + Lomb AQUALOX Contact Lenses 97
6.4 Jul 06, 2017: Visioneering Technologies Appoints Carol Baez as Executive Territory Manager for Orange County/San Diego 97
6.5 Jun 29, 2017: Visioneering Technologies Announces Connie Stewart as Territory Manager, Los Angeles 98
6.6 Jun 27, 2017: Visioneering Technologies Names Mark Rapoport as New CFO 98
6.7 Jun 22, 2017: Bausch + Lomb Named Most Trusted Contact Lens Solution Brand In Canada For Second Consecutive Year By Brandspark International 99
6.8 Jun 20, 2017: Visioneering Technologies Announces Dave Halverson as Territory Manager in Southern California 99
6.9 Jun 19, 2017: Valeant Appoints Arthur J. Shannon As Senior Vice President, Head Of Investor Relations And Communications 100
6.10 Jun 19, 2017: John Paulson Joins Valeant Board Of Directors 100
6.11 Jun 13, 2017: KAMRA Corneal Inlay Helps College Administrator End Her Blurry Near Vision and Dependence on Reading Glasses 100
6.12 Jun 10, 2017: Three-Year Study Indicates Pioneering Contact Lens Therapy Effective in Slowing Myopia Progression in Children by 59% 101
6.13 Jun 10, 2017: Three-year study says new contact lens therapy slows myopia progression in children by 59 percent 102
6.14 Jun 01, 2017: The Cooper Companies Announces Second Quarter 2017 Results 103
6.15 Jun 01, 2017: The Cooper Companies Announces Second Quarter 2017 Results 104
6.16 May 30, 2017: The German Court has Granted a Preliminary Injunction in Favour of VSY Biotechnology BV and Against Carl Zeiss Meditec 105
6.17 May 23, 2017: Presbia Provides Update on US Staged Pivotal Clinical Trial For Flexivue Microlens 106
6.18 May 22, 2017: Bausch + Lomb Introduces renu Advanced Formula Multi-Purpose Solution 106
6.19 May 11, 2017: Hoya Reports Fourth Quarter and Full-Year Financial Results 107
6.20 May 10, 2017: Carl Zeiss Meditec accelerates growth in the first six months of 2016/17 108
6.21 May 09, 2017: Valeant Announces First Quarter 2017 Results And Raises Full Year Adjusted EBITDA Guidance Range 109
6.22 May 08, 2017: ZEISS Appoints New Fellow 109
6.23 May 08, 2017: Dr. Stephen S. Lane joins Alcon as Chief Medical Officer and Global Head Franchise Clinical Strategy 110
6.24 May 05, 2017: Valeant Announces Key Appointments In Dermatology And Corporate Communications Leadership 111
6.25 May 03, 2017: Presbia to Participate in the 2017 ASCRS Symposium & Congress in Los Angeles, California 112
6.26 May 02, 2017: KAMRA Corneal Inlay Utilizes Camera Technology to Sharpen and Clear Blurry Near Vision for Patients 112
6.27 May 01, 2017: Visioneering Technologies Expands US Sales Force 113
6.28 Apr 25, 2017: Novartis delivered sales growth across all divisions as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued 113
6.29 Apr 25, 2017: Essilor International: Revenue increases by 10% Q1 in line with planned 2017 growth trajectory 117
6.30 Apr 04, 2017: Carl Zeiss Meditec Group achieves first half 2016/17 revenue of approximately EUR 588 million 120
6.31 Mar 30, 2017: Bausch + Lomb ULTRA For Astigmatism Contact Lenses Introduced 120
6.32 Mar 27, 2017: Visioneering Technologies Successfully Lists on ASX 121
6.33 Mar 15, 2017: Bausch + Lomb Introduces Biotrue ONEday For Astigmatism Contact Lenses 122
6.34 Mar 08, 2017: The KAMRA Corneal Inlay Brings Life Back into Focus for Patients with Presbyopia, Blurring Near Vision 122
6.35 Mar 03, 2017: Visioneering Technologies Announces Launch of NaturalVue Sphere 1 Day Contact Lenses 123
6.36 Mar 02, 2017: Johnson & Johnson Vision Expands Portfolio to Reach More Patients with ACUVUE OASYS 1-DAY Brand Contact Lenses for ASTIGMATISM 124
6.37 Mar 02, 2017: The Cooper Companies Announces First Quarter Results 124
6.38 Feb 28, 2017: Valeant Reports Fourth Quarter And Full Year 2016 Financial Results And Provides 2017 Guidance 125
6.39 Feb 28, 2017: Novartis shareholders approve all resolutions proposed by Board of Directors at the Annual General Meeting 129
6.40 Feb 17, 2017: Essilor International Reports 2016 Financial Results 130
6.41 Feb 10, 2017: Carl Zeiss Meditec Off to A Solid Start Into Business Year 2016/17 137
6.42 Jan 31, 2017: Hoya Announces Third Quarter Financial Results 138
6.43 Jan 26, 2017: Novartis highlights progress towards access and environmental goals in 2016 Corporate Responsibility Performance Report 138
6.44 Jan 26, 2017: Achievement of sales milestone for COPD products 139
6.45 Jan 25, 2017: Novartis delivered solid 2016 performance, with Growth Products absorbing Gleevec US LOE; innovation momentum continued; announces share buyback 140
6.46 Jan 24, 2017: Visioneering Technologies Announces Pam Wyman as Director, Sales Operations & Inside Sales 147
6.47 Jan 18, 2017: Bausch + Lomb Introduces Zen RC Scleral Contact Lenses 147
6.48 Jan 17, 2017: Visioneering Technologies Announces Jeff Babbe as New Executive Territory Manager for Chicago, IL 148
6.49 Jan 11, 2017: Paragon CRT Contact Lenses Approved by China Food & Drug Administration 148
6.50 Jan 10, 2017: Bausch + Lomb Launches Expanded Parameters For Bausch + Lomb ULTRA For Presbyopia Contact Lenses 149
6.51 Jan 10, 2017: Bausch + Lomb ULTRA for Presbyopia Contact Lenses Parameters Expanded 150
6.52 Jan 10, 2017: Stephen Petranek Appointed to NexOptic Board 150
6.53 Jan 04, 2017: Valeant Pharmaceuticals Announces Addition Of Richard U. DeSchutter To Its Board Of Directors 151
6.54 Jan 04, 2017: First Contact Lenses Specifically Designed for Digital Lifestyles Makes their CES Debut 152
6.55 Dec 21, 2016: Visioneering Technologies Announces Brian Atkinson as Territory Manager for the Dallas/Ft. Worth Market 153
6.56 Dec 13, 2016: Visioneering Technologies Announces Ken Gold as New Executive Territory Manager for the Baltimore-Washington, DC Area 153
6.57 Dec 12, 2016: Bausch + Lomb Specialty Vision Products Launches New 28 Lens Zenlens Dx Set 154
6.58 Dec 12, 2016: Valeant Appoints William D. Humphries As EVP, Dermatology 154
6.59 Dec 09, 2016: Carl Zeiss Meditec continues its growth trend 155
6.60 Dec 08, 2016: The Cooper Companies Announces Fourth Quarter and Full Year 2016 Results 156
6.61 Dec 07, 2016: Essilor Realigns its Organization with its Growing Businesses 157
6.62 Dec 07, 2016: VTI names executive director of manufacturing and engineering 158
6.63 Dec 07, 2016: Visioneering Technologies Announces Ms. Rosa Lee as New Executive Director of Manufacturing & Engineering 158
6.64 Nov 29, 2016: Novartis Access shares one-year learnings and announces memorandum of understanding with Rwanda 159
6.65 Nov 17, 2016: Former Valeant Executive And Former Philidor Ceo Charged In Manhattan Federal Court For Illegal Fraud And Kickback Scheme 160
6.66 Nov 10, 2016: Alcon introduces new AIR OPTIX plus HydraGlyde monthly replacement contact lenses at the American Academy of Optometry annual meeting 161
6.67 Nov 09, 2016: New Study Shows Groundbreaking Contact Lens Therapy Effective in Slowing Myopia Progression in Children by 59% Over Two Years 162
6.68 Nov 09, 2016: Daniel B. Polley, Ph.D., appointed Director of Lauer Tinnitus Research Center at Mass. Eye and Ear 164
6.69 Nov 08, 2016: Valeant Reports Third Quarter 2016 Financial Results 165
6.70 Oct 28, 2016: Hoya Reports Second Quarter Results 168
6.71 Oct 27, 2016: VTI Introduces the NaturalVue Multifocal QuickStart Calculator 169
6.72 Oct 26, 2016: Edmund Optics and Varioptic Announce the Availability of the Variable Focus Arctic Liquid Lens in the EO Catalog 169
6.73 Oct 25, 2016: Novartis delivered solid third quarter with Growth Products offsetting Gleevec patent expiration; several positive readouts for potential blockbusters 170
6.74 Oct 21, 2016: Essilor: Nine-Month Consolidated Revenue up 7.8% at Constant Exchange Rates 177
6.75 Oct 13, 2016: Carl Zeiss Meditec appoints Steven C. Schallhorn, MD as Chief Medical Officer 179
6.76 Oct 12, 2016: Bausch + Lomb Booth to Feature Wet Lab During the Annual Meeting of the American Academy of Ophthalmology in Chicago 180
6.77 Oct 06, 2016: Valeant Appoints Louis W. Yu, Ph.D. As Chief Quality Officer 182
6.78 Sep 01, 2016: The Cooper Companies CFO Gregory W. Matz to Retire; Albert G. White Named Successor in Planned Transition 183
6.79 Sep 01, 2016: The Cooper Companies Announces Third Quarter 2016 Results 184
6.80 Aug 29, 2016: Drug-dispensing contact lens effectively lowers eye pressure in pre-clinical glaucoma model 184
6.81 Aug 29, 2016: Drug Dispensing Contact lens Effectively Lowers Eye Pressure in Pre clinical Glaucoma Model 186
6.82 Aug 22, 2016: Valeant Pharmaceuticals Appoints Paul S. Herendeen As Executive Vice President, Finance And Chief Financial Officer 187
6.83 Aug 15, 2016: CooperVision Unveils Avaira Vitality Sphere and Toric Two-Week Contact Lenses 188
6.84 Aug 12, 2016: Carl Zeiss Meditec Grows in Ophthalmology and Microsurgery 189
6.85 Aug 11, 2016: Outcomes of Presbia Microlens Surgeries in Korean Study Demonstrate Excellent Results 190
6.86 Aug 10, 2016: Valeant Pharmaceuticals Comments On SDNY Investigation 190
6.87 Aug 09, 2016: Valeant Pharmaceuticals Reports Second Quarter 2016 Financial Results 190
6.88 Aug 08, 2016: Valeant Pharmaceuticals Announces Changes To Executive Management Team 192
6.89 Aug 01, 2016: Essilor International: Improving Lives by Improving Sight 194
6.90 Jul 29, 2016: Essilor - First-Half 2016 Results: Revenue Up 8.1% Excluding the Currency Effect 195
6.91 Jul 29, 2016: Hoya Reports First Quarter Financial Results 199
6.92 Jul 28, 2016: Valeant Pharmaceuticals Announces The Addition Of Sarah B. Kavanagh To Its Board Of Directors 199
6.93 Jul 27, 2016: Carl Zeiss Meditec Recruits James V. Mazzo to Lead Its Newly Consolidated Ophthalmology Organization 200
7 Appendix 201
7.1 Methodology 201
7.2 About GlobalData 204
7.3 Contact Us 204
7.4 Disclaimer 204

1.1 List of Tables
Table 1: Contact Lenses - Pipeline Products by Stage of Development 13
Table 2: Contact Lenses - Pipeline Products by Segment 14
Table 3: Contact Lenses - Pipeline Products by Territory 15
Table 4: Contact Lenses - Pipeline Products by Regulatory Path 16
Table 5: Contact Lenses - Pipeline Products by Estimated Approval Date 17
Table 6: Contact Lenses - Ongoing Clinical Trials 18
Table 7: Contact Lenses Companies - Pipeline Products by Stage of Development 19
Table 8: Contact Lenses - Pipeline Products by Stage of Development 21
Table 9: Aeon Astron Corporation Pipeline Products & Ongoing Clinical Trials Overview 23
Table 10: Biolens - Product Status 23
Table 11: Biolens - Product Description 23
Table 12: Contact Lens - Product Status 24
Table 13: Contact Lens - Product Description 24
Table 14: Alcon Laboratories Inc Pipeline Products & Ongoing Clinical Trials Overview 25
Table 15: AIR OPTIX Plus HydraGlyde Monthly Replacement Clear And Color Lens - Product Status 25
Table 16: AIR OPTIX Plus HydraGlyde Monthly Replacement Clear And Color Lens - Product Description 26
Table 17: AIR OPTIX Plus HydraGlyde Monthly Replacement Contact Lenses - Overnight And Flexible Wear - Product Status 26
Table 18: AIR OPTIX Plus HydraGlyde Monthly Replacement Contact Lenses - Overnight And Flexible Wear - Product Description 26
Table 19: Dailies Total 1 Colors SiHy Lens - Product Status 27
Table 20: Dailies Total 1 Colors SiHy Lens - Product Description 27
Table 21: Dailies Total 1 Toric SiHy Lens - Product Status 27
Table 22: Dailies Total 1 Toric SiHy Lens - Product Description 27
Table 23: Smart Contact Lens - Diabetes - Product Status 28
Table 24: Smart Contact Lens - Diabetes - Product Description 28
Table 25: Weekly WG SiHy Lens - Product Status 28
Table 26: Weekly WG SiHy Lens - Product Description 29
Table 27: Alcon Laboratories Inc - Ongoing Clinical Trials Overview 30
Table 28: AIR OPTIX Plus HydraGlyde Monthly Replacement Contact Lenses - Overnight And Flexible Wear - Clinical Assessment of a Regimen of AIR OPTIX plus HYDRAGLYDE Silicone Hydrogel Lenses and HYDRAGLYDE Containing Lens Care Solutions 31
Table 29: AIR OPTIX Plus HydraGlyde Monthly Replacement Contact Lenses - Overnight And Flexible Wear - One-month Clinical Comparison of Silicone Hydrogel Monthly Lenses in High Lipid Depositors 31
Table 30: AIR OPTIX Plus HydraGlyde Monthly Replacement Clear And Color Lens - One-month Clinical Comparison of Silicone Hydrogel Monthly Lenses in High Lipid Depositors 32
Table 31: Apeliotus Ophthalmics (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 33
Table 32: Comfort Lens - Product Status 33
Table 33: Comfort Lens - Product Description 33
Table 34: Contact Lens - Glaucoma - Product Status 34
Table 35: Contact Lens - Glaucoma - Product Description 34
Table 36: Auburn University Pipeline Products & Ongoing Clinical Trials Overview 35
Table 37: Smart Contact Lenses - Product Status 35
Table 38: Smart Contact Lenses - Product Description 35
Table 39: Axcelon Biopolymers Corp. Pipeline Products & Ongoing Clinical Trials Overview 36
Table 40: MC - PHEMA Based Contact Lens - Product Status 36
Table 41: MC - PHEMA Based Contact Lens - Product Description 36
Table 42: Bar-Ilan University Pipeline Products & Ongoing Clinical Trials Overview 37
Table 43: Bionic Contact Lens - Product Status 37
Table 44: Bionic Contact Lens - Product Description 37
Table 45: Bausch & Lomb Inc Pipeline Products & Ongoing Clinical Trials Overview 38
Table 46: Bausch + Lomb ULTRA Astigmatism Contact Lens - Product Status 38
Table 47: Bausch + Lomb ULTRA Astigmatism Contact Lens - Product Description 39
Table 48: Bausch + Lomb ULTRA Presbyopia Contact Lens - Product Status 39
Table 49: Bausch + Lomb ULTRA Presbyopia Contact Lens - Product Description 40
Table 50: Ultra Plus Powers Lens - Product Status 40
Table 51: Ultra Plus Powers Lens - Product Description 41
Table 52: Ultra Toric Lens - Product Status 41
Table 53: Ultra Toric Lens - Product Description 41
Table 54: Children's Hospital Boston Pipeline Products & Ongoing Clinical Trials Overview 42
Table 55: Contact Lens Drug Delivery Device - Product Status 42
Table 56: Contact Lens Drug Delivery Device - Product Description 42
Table 57: CooperVision Inc Pipeline Products & Ongoing Clinical Trials Overview 43
Table 58: Biofinity Energys - Product Status 43
Table 59: Biofinity Energys - Product Description 43
Table 60: MiSight Dual-Focus Myopia Control 1-Day Soft Contact Lens - Product Status 44
Table 61: MiSight Dual-Focus Myopia Control 1-Day Soft Contact Lens - Product Description 44
Table 62: SiH Multifocal - Product Status 44
Table 63: SiH Multifocal - Product Description 45
Table 64: CooperVision Inc - Ongoing Clinical Trials Overview 46
Table 65: MiSight Dual-Focus Myopia Control 1-Day Soft Contact Lens - A Multi-center Dispensing Clinical Evaluation of MiSight Lenses 47
Table 66: MiSight Dual-Focus Myopia Control 1-Day Soft Contact Lens - Efficacy and Safety of MiSight Contact Lenses in Reducing the Progression of Childhood Myopia, Not Pathological, Aged 8-12 Years Randomized Clinical Trial 47
Table 67: EP Global Communications, Inc. Pipeline Products & Ongoing Clinical Trials Overview 48
Table 68: EP Global Contact Lens - Product Status 48
Table 69: EP Global Contact Lens - Product Description 48
Table 70: Euclid Systems Corp Pipeline Products & Ongoing Clinical Trials Overview 49
Table 71: Drug-Eluting Contact Lenses - Product Status 49
Table 72: Drug-Eluting Contact Lenses - Product Description 49
Table 73: e-Vision Medical Devices, Inc. Pipeline Products & Ongoing Clinical Trials Overview 50
Table 74: Electronic Contact Lens - Product Status 50
Table 75: Electronic Contact Lens - Product Description 50
Table 76: Eyenovations Pipeline Products & Ongoing Clinical Trials Overview 51
Table 77: Drug Dispensing Contact Lens - Product Status 51
Table 78: Drug Dispensing Contact Lens - Product Description 51
Table 79: EyeYon Medical Pipeline Products & Ongoing Clinical Trials Overview 52
Table 80: Hyper-CL - Drug Delivery - Product Status 52
Table 81: Hyper-CL - Drug Delivery - Product Description 52
Table 82: Imperial College London Pipeline Products & Ongoing Clinical Trials Overview 53
Table 83: Contact Lens - Product Status 53
Table 84: Contact Lens - Product Description 53
Table 85: Johnson & Johnson Vision Care Inc Pipeline Products & Ongoing Clinical Trials Overview 54
Table 86: 1-DAY ACUVUE Multifocal Contact Lens - Product Status 54
Table 87: 1-DAY ACUVUE Multifocal Contact Lens - Product Description 54
Table 88: Anti-allergic Contact Lens - Product Status 55
Table 89: Anti-allergic Contact Lens - Product Description 55
Table 90: Massachusetts Eye and Ear Infirmary Pipeline Products & Ongoing Clinical Trials Overview 56
Table 91: Therapeutic Contact Lens - Product Status 56
Table 92: Therapeutic Contact Lens - Product Description 56
Table 93: Novartis AG Pipeline Products & Ongoing Clinical Trials Overview 57
Table 94: CLM041 - Product Status 57
Table 95: CLM041 - Product Description 57
Table 96: Ocular Dynamics, LLC Pipeline Products & Ongoing Clinical Trials Overview 58
Table 97: Contact Lens - Dry Eye Disease - Product Status 58
Table 98: Contact Lens - Dry Eye Disease - Product Description 58
Table 99: Ocutec Ltd Pipeline Products & Ongoing Clinical Trials Overview 59
Table 100: Third PEG Hydrogel Contact Lens - Product Status 59
Table 101: Third PEG Hydrogel Contact Lens - Product Description 59
Table 102: Presbia Plc Pipeline Products & Ongoing Clinical Trials Overview 60
Table 103: Presbia Flexivue Microlens - Product Status 60
Table 104: Presbia Flexivue Microlens - Product Description 60
Table 105: Presbia Plc - Ongoing Clinical Trials Overview 61
Table 106: Presbia Flexivue Microlens - Prospective, Non-randomized, Unmasked, Multicenter Clinical Investigation of the Presbia Flexivue Microlens for the Improvement of Near Vision in Emmetropic Presbyopes 62
Table 107: RetMap Inc Pipeline Products & Ongoing Clinical Trials Overview 63
Table 108: CLEAr Lens - Product Status 63
Table 109: CLEAr Lens - Product Description 63
Table 110: Stanford University Pipeline Products & Ongoing Clinical Trials Overview 64
Table 111: Polymer Network Hydrogel Contact Lens - Product Status 64
Table 112: Polymer Network Hydrogel Contact Lens - Product Description 64
Table 113: SynergEyes Inc Pipeline Products & Ongoing Clinical Trials Overview 65
Table 114: Duette Progressive With Tangible Hydra-PEG - Product Status 65
Table 115: Duette Progressive With Tangible Hydra-PEG - Product Description 65
Table 116: Duette With Tangible Hydra-PEG - Product Status 66
Table 117: Duette With Tangible Hydra-PEG - Product Description 66
Table 118: The Hong Kong University of Science and Technology Pipeline Products & Ongoing Clinical Trials Overview 67
Table 119: Resonance Circuit Sensor Contact Lens - Product Status 67
Table 120: Resonance Circuit Sensor Contact Lens - Product Description 67
Table 121: The University of New South Wales Pipeline Products & Ongoing Clinical Trials Overview 68
Table 122: Stem Cell Contact Lens - Product Status 68
Table 123: Stem Cell Contact Lens - Product Description 68
Table 124: UltraVision CLPL Pipeline Products & Ongoing Clinical Trials Overview 69
Table 125: Contact Lenses - Product Status 69
Table 126: Contact Lenses - Product Description 69
Table 127: University of California San Diego Pipeline Products & Ongoing Clinical Trials Overview 70
Table 128: Aerated Contact Lens - Product Status 70
Table 129: Aerated Contact Lens - Product Description 70
Table 130: Telescopic Contact Lens - Product Status 71
Table 131: Telescopic Contact Lens - Product Description 71
Table 132: University of Florida Pipeline Products & Ongoing Clinical Trials Overview 72
Table 133: Vitamin E - Packed Lenses - Product Status 72
Table 134: Vitamin E - Packed Lenses - Product Description 72
Table 135: University of Valencia Pipeline Products & Ongoing Clinical Trials Overview 73
Table 136: Multifocal Contact Lens - Myopia - Product Status 73
Table 137: Multifocal Contact Lens - Myopia - Product Description 73
Table 138: Multifocal Contact Lens - Presbyopia - Product Status 74
Table 139: Multifocal Contact Lens - Presbyopia - Product Description 74
Table 140: University of Washington Pipeline Products & Ongoing Clinical Trials Overview 75
Table 141: Bionic Contact Lens - Product Status 75
Table 142: Bionic Contact Lens - Product Description 75
Table 143: Solar Powered Augmented Lenses - Product Status 76
Table 144: Solar Powered Augmented Lenses - Product Description 76
Table 145: Valeant Pharmaceuticals International Inc Pipeline Products & Ongoing Clinical Trials Overview 77
Table 146: Biotrue ONEday Toric Lenses - ASTIGMATISM - Product Status 78
Table 147: Biotrue ONEday Toric Lenses - ASTIGMATISM - Product Description 78
Table 148: BLC - 001: SVS - Product Status 78
Table 149: BLC - 001: SVS - Product Description 79
Table 150: BLC - 002: SVS - Product Status 79
Table 151: BLC - 002: SVS - Product Description 79
Table 152: BLC - 003: SVS/MF/fA - Product Status 80
Table 153: BLC - 003: SVS/MF/fA - Product Description 80
Table 154: BLC - 004: Toric - Product Status 80
Table 155: BLC - 004: Toric - Product Description 81
Table 156: BLC - 005: SVS/MF - Product Status 81
Table 157: BLC - 005: SVS/MF - Product Description 81
Table 158: BLC - 006: SVS - Product Status 82
Table 159: BLC - 006: SVS - Product Description 82
Table 160: BLC - 007: MF - Product Status 82
Table 161: BLC - 007: MF - Product Description 83
Table 162: BLC - 008: Astigmatism - Product Status 83
Table 163: BLC - 008: Astigmatism - Product Description 83
Table 164: BLC - 009: Astigmatism - Product Status 83
Table 165: BLC - 009: Astigmatism - Product Description 84
Table 166: XUV - 003: Aphakia - Product Status 84
Table 167: XUV - 003: Aphakia - Product Description 84
Table 168: XUV - 004: SVS - Product Status 84
Table 169: XUV - 004: SVS - Product Description 85
Table 170: XUV - 007: MF - Product Status 85
Table 171: XUV - 007: MF - Product Description 85
Table 172: XUV - 009: SVS - Product Status 86
Table 173: XUV - 009: SVS - Product Description 86
Table 174: XUV - 010: Astigmatism - Product Status 86
Table 175: XUV - 010: Astigmatism - Product Description 87
Table 176: XUV - 011: MF - Product Status 87
Table 177: XUV - 011: MF - Product Description 87
Table 178: XUV - 012: SVS - Product Status 87
Table 179: XUV - 012: SVS - Product Description 88
Table 180: XUV - 013: Astigmatism - Product Status 88
Table 181: XUV - 013: Astigmatism - Product Description 88
Table 182: XUV - 014: Presbyopia - Product Status 89
Table 183: XUV - 014: Presbyopia - Product Description 89
Table 184: XUV - 015: MF - Product Status 89
Table 185: XUV - 015: MF - Product Description 89
Table 186: Visioneering Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 90
Table 187: Contact Lens - Product Status 90
Table 188: Contact Lens - Product Description 90
Table 189: NaturalVue (etafilcon A) Sphere 1 Day Contact Lenses - Product Status 91
Table 190: NaturalVue (etafilcon A) Sphere 1 Day Contact Lenses - Product Description 91
Table 191: NaturalVue Toric 1 Day Contact Lenses - Product Status 91
Table 192: NaturalVue Toric 1 Day Contact Lenses - Product Description 92
Table 193: NaturalVue Toric Multifocal 1 Day Contact Lenses - Product Status 92
Table 194: NaturalVue Toric Multifocal 1 Day Contact Lenses - Product Description 92
Table 195: VTI MPC Lens - Product Status 93
Table 196: VTI MPC Lens - Product Description 93
Table 197: VISTAKON Pharmaceuticals LLC Pipeline Products & Ongoing Clinical Trials Overview 94
Table 198: K-Lens - Product Status 94
Table 199: K-Lens - Product Description 94
Table 200: Yolia Health Pipeline Products & Ongoing Clinical Trials Overview 95
Table 201: TVT Device - Product Status 95
Table 202: TVT Device - Product Description 95
Table 203: Glossary 203

1.2 List of Figures
Figure 1: Contact Lenses - Pipeline Products by Stage of Development 13
Figure 2: Contact Lenses - Pipeline Products by Segment 14
Figure 3: Contact Lenses - Pipeline Products by Territory 15
Figure 4: Contact Lenses - Pipeline Products by Regulatory Path 16
Figure 5: Contact Lenses - Pipeline Products by Estimated Approval Date 17
Figure 6: Contact Lenses - Ongoing Clinical Trials 18
  • Optometry/Eye Exam Equipment Market by Type (OCT, Fundus Cameras, Perimeters, Ophthalmoscope, Ultrasound, Autorefractor, Slit Lamp, Corneal Topography, Lensmeter, Chart Projectors, Wavefront Analyzer), End User (Hospital, Clinic) - Global Forecast to 2022
    Published: 13-Dec-2017        Price: US 5650 Onwards        Pages: 209
    “The eye exam equipment market is projected to grow at a CAGR of 6.0% between 2017 and 2022.” The eye exam equipment market is expected to reach USD 3.05 billion by 2022 from USD 2.29 billion in 2017, at a CAGR of 6.0% from 2017 to 2022. Rising prevalence of eye diseases, technological advancements in ophthalmic devices, increasing government initiatives to control visual impairment, and increasing healthcare expenditure and rising disposable incomes are s......
  • Global Intraocular Lens (IOLs) Market Professional Survey Report 2017
    Published: 13-Dec-2017        Price: US 3500 Onwards        Pages: 117
    This report studies Intraocular Lens (IOLs) in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - ALCON - AMO (Abbott) - Bausch + Lomb - HOYA - CARL Ze......
  • Global Automatic Refractometers Market Research Report 2017
    Published: 12-Dec-2017        Price: US 2900 Onwards        Pages: 114
    In this report, the global Automatic Refractometers market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Automatic Refractometers in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - ......
  • United States Lacrimal Cannulae Market Report 2017
    Published: 12-Dec-2017        Price: US 3800 Onwards        Pages: 112
    In this report, the United States Lacrimal Cannulae market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth rate o......
  • Global Auto-keratometers Market Research Report 2017
    Published: 12-Dec-2017        Price: US 2900 Onwards        Pages: 122
    In this report, the global Auto-keratometers market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Auto-keratometers in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China -......
  • Global Eyesight Test Device Market Research Report 2017
    Published: 12-Dec-2017        Price: US 2900 Onwards        Pages: 110
    In this report, the global Eyesight Test Device market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Eyesight Test Device in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China......
  • Global Auto Lensmeter Market Research Report 2017
    Published: 12-Dec-2017        Price: US 2900 Onwards        Pages: 111
    In this report, the global Auto Lensmeter market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Auto Lensmeter in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China - Japan......
  • Global Diagnostic Ophthalmic Devices Market Research Report 2017
    Published: 12-Dec-2017        Price: US 2900 Onwards        Pages: 116
    In this report, the global Diagnostic Ophthalmic Devices market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Diagnostic Ophthalmic Devices in these regions, from 2012 to 2022 (forecast), covering - North America - Europe......
  • China Artificial Lens Market Research Report 2017
    Published: 11-Dec-2017        Price: US 3400 Onwards        Pages: 107
    The global Artificial Lens market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. China plays an important role in global market, with market size of xx million USD in 2016 and will be xx million USD in 2022, with a CAGR of xx%. This report studies the Artificial Lens development status and future trend in China, focuses on top players in China, also splits Artificial Len......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs